Back to top

BioMarin price target raised to $76 from $75 at Citi

Citi analyst Eric Joseph raised the firm’s price target on BioMarin (BMRN) to $76 from $75 and keeps a Buy rating on the shares. The firm adjusted ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)